Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

12/3/2024

Janusmed kön och genus

Janusmed kön och genus – Vinorelbine medac

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Vinorelbin Testmiljö

Vinorelbin

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Socialstyrelsen. Cancer i siffror 2018. Socialstyrelsen [www]. [updated 2018-06-10, cited 2020-10-01].

  2. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.

  3. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.

  4. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.

  5. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.

  6. de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2000;119(1):21-6.

  7. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990;8(8):1402-7.

  8. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850-6.

  9. Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78(1):209-15; discussion 215.

  10. Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?. Lung Cancer. 2009;66(2):262-7.

  11. Hamimed M, Leblond P, Dumont A, Gattacceca F, Tresch-Bruneel E, Probst A et al. Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis. Cancer Chemother Pharmacol. 2022;90(1):29-44.

  12. Freyer G, Tranchand B, Ligneau B, Ardiet C, Souquet PJ, Court-Fortune I et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol. 2000;50(4):315-24.

  13. Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA et al. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013;14(6):627-35.

  14. Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res. 2005;11(15):5481-6.

  15. Navirel (vinorelbin). Swedish Medical Products Agency [updated 2020-09-16, cited 2023-03-07]

  16. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]

  1. Socialstyrelsen. Cancer i siffror 2018. Socialstyrelsen [www]. [updated 2018-06-10, cited 2020-10-01].
  2. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
  3. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
  4. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
  5. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.
  6. de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2000;119(1):21-6.
  7. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990;8(8):1402-7.
  8. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850-6.
  9. Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78(1):209-15; discussion 215.
  10. Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?. Lung Cancer. 2009;66(2):262-7.
  11. Hamimed M, Leblond P, Dumont A, Gattacceca F, Tresch-Bruneel E, Probst A et al. Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis. Cancer Chemother Pharmacol. 2022;90(1):29-44.
  12. Freyer G, Tranchand B, Ligneau B, Ardiet C, Souquet PJ, Court-Fortune I et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol. 2000;50(4):315-24.
  13. Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA et al. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013;14(6):627-35.
  14. Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res. 2005;11(15):5481-6.
  15. Navirel (vinorelbin). Swedish Medical Products Agency [updated 2020-09-16, cited 2023-03-07]
  16. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]